Select acquires remainder of subsidiaries

By Melissa Trudinger
Tuesday, 30 November, 2004

Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.

The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.

Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.

An international team of researchers has used genetic engineering to create so-called...

An international study has found concerning evidence about the impact of a range of common...

Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...

Content from other channels on our network

Handmade Food + High-Growth Systems: How Fishbowl scaled up Adelia's Operations

The Arnott's Group appoints its Chief People Officer

Furthering the NoLo advantage this festive season

PEAL Is Here: Why Front-End Allergen Control Matters More Than Ever

Pure Foods Tasmania adds dairy to its ice cream portfolio

Siemens showcases AI that autonomously executes engineering tasks

Advantech partners with D3 Embedded on AMR sensing and computing

ARC announces $34m in collaborative research funding

Brisbane biomanufacturing hub signs its first tenant

Carbon280 seeks further funding for Hydrilyte technology

Condensate and Cooling Water Monitoring and Aromatics Detection

Agreement unites clean energy providers

Deal to create graphene-based carbon paste used in solar

Net zero or 1.2 million homes: trade-off or win-win?

Mining waste provides strong boost to concrete construction